0.2520EUR-0.79%Mkt Cap: 13.44M EURP/E: —Last update: 2026-05-14
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)0.27
PEG—
P/B-0.22
P/S1.76
EV/EBITDA—
EV/Revenue9.59
EPS (TTM)-0.26
EPS (Forward)0.92
Cash Flow & Leverage
FCF Yield-75.97%
FCF Margin-133.37%
Operating CF-13.98M EUR
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt59.95M EUR
Technical
SMA 500.2609 (-3.4%)
SMA 2000.2895 (-13.0%)
Beta1.31
S&P 52W Chg24.23%
Avg Vol (30d)639.91K
Avg Vol (10d)141.24K
Technical Indicators
RSI (14)44.9
MACD-0.0029
MACD Signal-0.0021
MACD Hist.-0.0008
BB Upper0.2798 EUR
BB Middle0.2624 EUR
BB Lower0.2449 EUR
BB Width13.29%
ATR (14)0.0130 EUR
Vol Ratio (20d)0.73x
52W Range
0.21806% of range0.8300
52W High0.8300 EUR
52W Low0.2180 EUR
Profitability
Gross Margin52.02%
EBITDA Margin0.00%
Profit Margin-178.45%
Oper. Margin-89.97%
ROE—
ROA-20.72%
Revenue Growth87.90%
Earnings Growth—
Balance Sheet
Debt/Equity-0.96
Current Ratio0.26
Quick Ratio0.23
Book Value/Sh-1.1430 EUR
Cash/Share0.0380 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.53.66M
Float—
Insiders5.73%
Institutions4.99%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap13.44M EUR
Enterprise Value73.41M EUR
Revenue (TTM)7.66M EUR
Gross Profit3.98M EUR
Net Income (TTM)-13.66M EUR
Revenue/Share0.1440 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees5
Last Price0.2520 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012432516